Trial abstract · §3
IPA-PH2-POI — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Time to recovery of gastrointestinal function after abdominal surgery | The programme did not proceed. The Institute records that the only clinical development of this compound was in an indication unrelated to the uses under which it is supplied for research | Not rated |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Ipamorelin from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Injection-site reaction | — | — | Reported |
| Headache | — | — | Reported |
| Flushing | — | — | Reported |
| Transient hunger | — | — | Less than with non-selective secretagogues but reported |
| Fluid retention | — | — | Expected class effect |
| Glucose intolerance | — | — | Expected class effect; not systematically characterised |
Compound Evidence Institute · CEI-TR-0101/3 · https://compoundevidence.com/trials/ipa-ph2-poi/results/ · retrieved 30 July 2026